Qiagen

History

In 1984, QIAGEN was established on November 29 by a team of scientists at the Heinrich Heine University Düsseldorf, Germany. Two years later, QIAGEN launched its first product. A kit for the purification of plasmids—small ring-shaped DNA molecules in bacterial cells. 1996 saw the initial public offering of QIAGEN on the American technology-oriented Nasdaq stock exchange, becoming the first German company to do so. 1997 saw the initial public offering on the Frankfurt Stock Exchange in Germany.

Acquisitions and Business Development Timeline

In 2004, QIAGEN acquired key assets of Molecular Staging, Inc. Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales were US$649.8 million with more than 2,600 employees. QIAGEN acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention.

In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million and it acquired SABiosciences Corp. in a deal valued at US$90 million. During this year it released a clinically verified diagnostic test for the detection of H1N1, more commonly known as Swine Flu. During 2009 QIAGEN had over US$1 billion in revenue and over 3,500 employees.

In 2010, QIAGEN acquired ESE GmbH for point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure.

In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space. QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention. The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions.

In 2013, QIAGEN acquired Ingenuity Systems. QIAGEN also acquired CLC bio, which offers bioinformatics analysis software.

In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology. QIAGEN also acquired Enzymatic enzyme solutions. In March 2015, Qiagen divested its Marseille unit through a management buyout that led to the creation of HalioDx. In late 2015 the GeneReader NGS System was launched, and the acquisition of Mo Bio Laboratories was completed.

In 2016, QIAGEN acquired the Danish molecular diagnostics company Exiqon.

In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.

In 2018, QIAGEN transferred its U.S. listing to the New York Stock Exchange. In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform.

In 2019, QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform. An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, allowed it to expand its Qiagen Clinical Insights (QCI) bioinformatics offerings. In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize in vitro diagnostic kits to be used together with Illumina's diagnostic instruments.

In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. giving it two fully integrated systems for automated PCR.

In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.

In January 2023, the business announced its intention to acquire Verogen for $150 million. This deal included acquiring GEDmatch, a genetic genealogy service.

• Qiagen
  • Molecular Staging, Inc. (Acq 2004)
  • Digene (Acq 2007)
  • Corbett Life Science (Acq 2008)
  • DxS Ltd (Acq 2009)
  • SABiosciences Corp. (Acq 2009)
  • ESE GmbH (Acq 2010)
  • Ipsogen S.A. (Acq 2011)
  • Cellestis Limited (Acq 2011)
  • Ingenuity Systems (Acq 2013)
  • CLC bio (Acq 2013)
  • Exiqon (Acq 2016)
  • STAT-Dx (Acq 2018)
  • Formulatrix (Acq 2019)
  • OmicSoft (Acq 2017)
  • N-of-One (Acq 2019)
  • Molecular Staging, Inc. (Acq 2020)
  • NeuMoDx Molecular Inc (Acq 2020)
  • Verogen (Acq 2023)

2020 Thermo Fisher Acquisition Target

On March 3, 2020, Thermo Fisher Scientific announced plans for the acquisition of QIAGEN at €39 per share in cash, which valued the transaction at $11.5 billion at the time. The day after an open letter by hedge fund Davidson Kempner Capital Management, one of QIAGEN's largest shareholders, to reject the bid as undervalued, Thermo Fisher raised their tender by 10% to €43 per share, an advance of $1B in value.

The acquisition offer was terminated on August 13, 2020, having only reached the threshold of 47% shareholder approval, below the minimum 66.6% required as per the agreement. Because of the lapsed offer, QIAGEN was required to reimburse $95 million to Thermo Fisher in expenses.

Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc., which it did not already own, for about $234 million.

References

References

1. (11 March 2024). "2023 Annual Report (Form 20-F)". US Securities and Exchange Commission.
2. "Supervisory Board".
3. "Our global presence {{!}} QIAGEN".
4. (2024-02-20). "Company Presentation".
5. "Historical Development {{!}} QIAGEN".
6. Peter A. Brooke, Daniel Penrice. (Nov 10, 2009). "A Vision for Venture Capital: Realizing the Promise of Global Venture Capital and Private Equity (Winthrop Group)".
7. "Historical Development {{!}} QIAGEN".
8. "Qiagen Pays $28.5M Cash For Molecular Staging Technology".
9. "Netherlands' Qiagen buying Digene for $1.6 bln". Reuters.
10. "Qiagen raises capital, buys DxS".
11. "Qiagen Acquires SABiosciences for $90M".
12. "Qiagen Releases Influenza A/H1N1 Detection Kit for Research Purposes".
13. "QIAGEN Acquires ESE GmbH".
14. "Qiagen übernimmt Mehrheit von Ipsogen". Springer Medizin Verlag GmbH.
15. "Qiagen Completes Cellestis Acquisition".
16. "Qiagen to Cut 8-10 Percent of Workforce in Restructuring".
17. "Qiagen buys genetic data processor Ingenuity for $105 million".
18. "QIAGEN Acquires CLC Bio".
19. "QIAGEN Expands Leadership in Liquid Biopsies".
20. "Qiagen acquires Enzymatics, gains NGS partner ArcherDX". Questex LLC.
21. "French cancer Dx company born after management buyout at Qiagen unit". Questex LLC.
22. "Qiagen Launches GeneReader NGS System at AMP; Presents Performance Evaluation by Broad".
23. "Qiagen Projects Q4, 2015 Shortfalls; Reports Acquisition of Mo Bio Labs".
24. "Qiagen Completes Exiqon Tender Offer".
25. "Qiagen acquires Multi Omics Company to boost its Bioinformatics services". Labiotech UG.
26. "Qiagen To Transfer U.S. Listing Of Global Shares To Nyse".
27. "New Diagnostic Tests On the Way as Qiagen Snaps Up a Spanish Biotech". Labiotech UG.
28. "FORMULATRIX® digital PCR technology to be acquired by QIAGEN".
29. "QIAGEN To Acquire N-of-One, Inc. - Quick Facts". Insider Inc..
30. "Illumina and Qiagen Enter 15-Year Diagnostics Partnership". Mary Ann Liebert Inc., publishers.
31. "Qiagen completes takeover of PCR automation player NeuMoDx for $248M". Industry Dive.
32. "Qiagen Acquires Majority Stake in Enzyme Provider Blirt".
33. "Qiagen acquires DNA-biometrics firm Verogen in $150 mln deal".
34. (3 March 2020). "Thermo Fisher Expands Diagnostics Capabilities with $11.5 Billion Takeover of Qiagen". BioSpace.com.
35. (17 July 2020). "Thermo Fisher Ups QIAGEN Bid by $1 Billion". BioSpace.com.
36. (13 August 2020). "Thermo Fisher-Qiagen deal falls apart after failing to secure shareholder support". MedTechDive.com.
37. (13 August 2020). "Thermo Fisher's Qiagen bid fails after target gets COVID testing boost". Reuters.